



FOR IMMEDIATE RELEASE

Ashok J. Chavan Joins Cancer Prevention Pharmaceuticals as Vice President of CMC and Supply Chain

TUCSON, Arizona, February 24, 2020 – Cancer Prevention Pharmaceuticals, Inc., (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today the appointment of Ashok J. Chavan, Ph.D., as Vice President of CMC and Supply Chain.

Chavan will coordinate chemistry, manufacturing and controls operations along with supply chain activities across CPP's portfolio of product candidates, including its lead drug candidate, CPP-1X/sul, for the treatment of adults with familial adenomatous polyposis (FAP). FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. FAP patients have no approved pharmaceutical therapies. CPP is seeking regulatory approval in the US and EU.

CPP recently completed its FAP-310 clinical trial, a Phase 3 clinical trial comparing the performance of the combination of CPP-1X (eflornithine) and sulindac (sul) to each single agent alone in delaying progression to an FAP-related event, such as surgery. The safety profile of the combination did not significantly differ from that demonstrated by the single agents and did not pose any concerns for long-term use of the product.

“Ashok has more than 20 years’ experience managing CMC and supply chain operations required for regulatory filings and commercial development of new drugs,” said CPP CEO Jeff Jacob. “He will be a pivotal part of our efforts to win approval of CPP-1X/sul and bring this new drug to FAP patients.”

Chavan joins CPP from Insys Therapeutics, Inc. where he was vice president of pharmaceutical operations and was involved in all phases of product development, including regulatory submissions, commercial launch and manufacturing for all the company's products. He also held similar positions with Oakwood Laboratories LLC and Akorn, Inc.

Chavan has a Ph.D. in chemistry from the University of Kentucky and was a postdoctoral scholar in the university's College of Pharmacy and Biochemistry Department. He earned his Bachelor of Science degree in chemistry and Master of Science degree in organic chemistry from the University of Bombay.

About Cancer Prevention Pharmaceuticals, Inc.

Cancer Prevention Pharmaceuticals, Inc. (CPP) is developing therapeutics designed to reduce the risk of cancer and other diseases. CPP's pharmaco-prevention approach has been used with success in other disease categories such as cardiovascular, neurovascular, and infectious disease. In addition to the CPP FAP-310 trial, CPP is co-sponsoring with the National Cancer Institute (NCI) and SWOG a large Phase 3 trial in colon cancer survivors. CPP is also working collaboratively with nonprofit groups to support their clinical trials in neuroblastoma, gastric cancer, and early-onset type 1 diabetes. CPP is located in Tucson, Arizona. For more information, please visit www.canprevent.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements that approval of CPP-1X/sul could mean the first effective treatment for FAP patients who now have limited therapeutic options. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however any intent or obligation to update these forward-looking statements.

Investor Relations Contact: Amato and Partners, LLC, Investor Relations Counsel,
admin@amatoandpartners.com

Media: Christine Brannen, Cancer Prevention Pharmaceuticals, Inc., press@canprevent.com
+1.520.908.7774

###